R R

What Is Semaglutide?

Semaglutide is a prescription glucagon-like peptide-1 receptor agonist used in several medications with different approved indications. Ozempic and Rybelsus are used for type 2 diabetes, with additional cardiovascular or kidney-related indications depending on the product. Wegovy is used for chronic weight management and certain cardiovascular indications, while Wegovy injection is also approved for selected adults with metabolic dysfunction-associated steatohepatitis and liver fibrosis. Semaglutide is available as once-weekly injections and once-daily tablets. The products have different strengths, schedules, and eligibility requirements and should not be substituted without medical guidance. Semaglutide products carry a boxed warning concerning thyroid C-cell tumors observed in rodents.

Link to This Resource Page

Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.

To display this...

What Is Semaglutide?

Semaglutide is a prescription glucagon-like peptide-1 receptor agonist used in several medications with different approved indications. Ozempic and Rybelsus are used for type 2 diabetes, with additional cardiovascular or kidney-related indications depending on the product. Wegovy is used for chronic weight management and certain cardiovascular indications, while Wegovy injection is also approved for selected adults with metabolic dysfunction-associated steatohepatitis and liver fibrosis. Semaglutide is available as once-weekly injections and once-daily tablets. The products have different strengths, schedules, and eligibility requirements and should not be substituted without medical guidance. Semaglutide products carry a boxed warning concerning thyroid C-cell tumors observed in rodents.

read more about semaglutide ...

Copy this HTML:

Copy HTML Copied!

How Does Semaglutide Work?

Semaglutide activates glucagon-like peptide-1 receptors, which participate in blood glucose regulation, appetite signaling, and gastrointestinal activity. When blood sugar is elevated, semaglutide increases insulin secretion and reduces glucagon release. It also slows gastric emptying and acts on pathways involved in appetite and food intake. These combined actions can improve glycemic control and support weight reduction in eligible patients. Clinical studies have demonstrated additional cardiovascular benefits with certain formulations and reductions in kidney-related complications in specified populations. The medication does not replace insulin in type 1 diabetes and does not permanently cure obesity, type 2 diabetes, or metabolic liver disease.

What Conditions Does Semaglutide Treat?

Semaglutide products have different FDA-approved indications. Ozempic injection improves glycemic control in adults with type 2 diabetes and is approved for cardiovascular risk reduction in certain adults with type 2 diabetes and for reducing kidney-related risks in adults with type 2 diabetes and chronic kidney disease. Rybelsus tablets treat type 2 diabetes and reduce major cardiovascular event risk in specified adults. Wegovy injection treats obesity in adults and adolescents aged 12 years and older, overweight in eligible adults, and certain cardiovascular risks. Wegovy injection is also approved under accelerated approval for noncirrhotic MASH with F2 to F3 fibrosis in adults. Wegovy tablets are approved for adult weight management and related cardiovascular risk reduction.

How Should Semaglutide Be Taken?

Semaglutide dosing depends on the specific product and indication. Ozempic injection generally begins at 0.25 mg once weekly for four weeks, followed by a gradual increase to an appropriate maintenance dose. Wegovy injection also uses weekly dose escalation, with approved maintenance doses that vary by indication and include a higher-dose Wegovy HD option for selected adults. Oral Rybelsus is taken once daily immediately after waking with no more than four ounces of plain water, followed by a wait of at least 30 minutes before food or other medications. Wegovy tablets have their own oral dose-escalation schedule. Semaglutide products should not be combined or exchanged without clinician-directed instructions.

What Are the Side Effects and Warnings of Semaglutide?

Common adverse effects include nausea, vomiting, diarrhea, constipation, abdominal pain, and reduced appetite. Semaglutide products carry a boxed warning about thyroid C-cell tumors observed in rodents and are contraindicated in patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2. Serious risks include pancreatitis, gallbladder disease, dehydration-related kidney injury, severe gastrointestinal reactions, and hypersensitivity. Diabetic retinopathy complications have been reported with semaglutide, particularly in patients with existing retinopathy. Hypoglycemia risk increases when used with insulin or certain diabetes medications. Severe abdominal pain, dehydration, or new vision changes require medical assessment.

Common Questions About Semaglutide

Are Ozempic, Rybelsus, and Wegovy the same medication?

All contain semaglutide, but they have different formulations, strengths, dosing instructions, and FDA-approved indications. They should not be substituted without medical direction.

Is semaglutide available as a pill?

Yes. Rybelsus and Wegovy tablets contain oral semaglutide. Their approved uses and dosing schedules differ.

Can semaglutide treat obesity?

Yes. Wegovy is approved for long-term weight management in specified adults, with the injectable formulation also approved for eligible adolescents aged 12 years and older.

Can semaglutide cause vision problems?

Diabetic retinopathy complications have been reported during semaglutide treatment. Patients with existing diabetic retinopathy may require monitoring, and new vision changes should be evaluated promptly.

References

DailyMed - OZEMPIC (semaglutide) injection, solution. https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=OZEMPIC. Date Accessed November 6, 2026.

Semaglutide. LiverTox. https://www.ncbi.nlm.nih.gov/books/NBK548574/. Date Accessed November 6, 2026.

Semaglutide. MedlinePlus. https://medlineplus.gov/druginfo/meds/a619057.html. Date Accessed November 6, 2026.

Semaglutide. PubChem. https://pubchem.ncbi.nlm.nih.gov/compound/56843331. Date Accessed November 6, 2026.

Semaglutide Injection. MedlinePlus. https://medlineplus.gov/druginfo/meds/a618008.html. Date Accessed November 6, 2026.